Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 4.93 trillion. The enterprise value is 5.12 trillion.
Important Dates
The last earnings date was Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Mar 30, 2027 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 55.77% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 12.83 and the forward PE ratio is 12.97.
| PE Ratio | 12.83 |
| Forward PE | 12.97 |
| PS Ratio | 2.07 |
| PB Ratio | 2.49 |
| P/TBV Ratio | 8.09 |
| P/FCF Ratio | 10.04 |
| P/OCF Ratio | 9.01 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 6.76, with an EV/FCF ratio of 10.42.
| EV / Earnings | 13.28 |
| EV / Sales | 2.15 |
| EV / EBITDA | 6.76 |
| EV / EBIT | 9.17 |
| EV / FCF | 10.42 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.21.
| Current Ratio | 1.31 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | 0.86 |
| Interest Coverage | 64.47 |
Financial Efficiency
Return on equity (ROE) is 21.44% and return on invested capital (ROIC) is 20.42%.
| Return on Equity (ROE) | 21.44% |
| Return on Assets (ROA) | 11.05% |
| Return on Invested Capital (ROIC) | 20.42% |
| Return on Capital Employed (ROCE) | 23.08% |
| Weighted Average Cost of Capital (WACC) | 4.25% |
| Revenue Per Employee | 168.81M |
| Profits Per Employee | 27.35M |
| Employee Count | 14,099 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.44 |
Taxes
In the past 12 months, Astellas Pharma has paid 113.96 billion in taxes.
| Income Tax | 113.96B |
| Effective Tax Rate | 22.82% |
Stock Price Statistics
The stock price has increased by +43.76% in the last 52 weeks. The beta is 0.04, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | +43.76% |
| 50-Day Moving Average | 2,439.33 |
| 200-Day Moving Average | 2,357.13 |
| Relative Strength Index (RSI) | 65.26 |
| Average Volume (20 Days) | 6,558,540 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 2.38 trillion and earned 385.58 billion in profits. Earnings per share was 214.51.
| Revenue | 2.38T |
| Gross Profit | 1.92T |
| Operating Income | 560.27B |
| Pretax Income | 499.44B |
| Net Income | 385.58B |
| EBITDA | 759.08B |
| EBIT | 560.27B |
| Earnings Per Share (EPS) | 214.51 |
Full Income Statement Balance Sheet
The company has 238.23 billion in cash and 424.92 billion in debt, with a net cash position of -186.69 billion or -104.12 per share.
| Cash & Cash Equivalents | 238.23B |
| Total Debt | 424.92B |
| Net Cash | -186.69B |
| Net Cash Per Share | -104.12 |
| Equity (Book Value) | 1.98T |
| Book Value Per Share | 1,105.17 |
| Working Capital | 344.58B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 547.65 billion and capital expenditures -56.18 billion, giving a free cash flow of 491.47 billion.
| Operating Cash Flow | 547.65B |
| Capital Expenditures | -56.18B |
| Depreciation & Amortization | 198.81B |
| Net Borrowing | -318.31B |
| Free Cash Flow | 491.47B |
| FCF Per Share | 274.08 |
Full Cash Flow Statement Margins
Gross margin is 80.84%, with operating and profit margins of 23.54% and 16.20%.
| Gross Margin | 80.84% |
| Operating Margin | 23.54% |
| Pretax Margin | 20.98% |
| Profit Margin | 16.20% |
| EBITDA Margin | 31.89% |
| EBIT Margin | 23.54% |
| FCF Margin | 20.65% |
Dividends & Yields
This stock pays an annual dividend of 80.00, which amounts to a dividend yield of 2.91%.
| Dividend Per Share | 80.00 |
| Dividend Yield | 2.91% |
| Dividend Growth (YoY) | 2.56% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 36.24% |
| FCF Payout Ratio | 29.19% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 2.89% |
| Earnings Yield | 7.80% |
| FCF Yield | 9.96% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for Astellas Pharma is 2,632.86, which is -4.31% lower than the current price. The consensus rating is "Buy".
| Price Target | 2,632.86 |
| Price Target Difference | -4.31% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | -2.39% |
| EPS Growth Forecast (3Y) | 0.32% |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 3.28 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.28 |
| Piotroski F-Score | 7 |